Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma.
F-18-Fluorodeoxyglucose
Kaposi sarcoma
diagnostic accuracy
disease staging
positron emission tomography/computed tomography
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Apr 2022
27 Apr 2022
Historique:
received:
16
03
2022
revised:
15
04
2022
accepted:
21
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
Positron emission tomography/computed tomography with fluorodeoxyglucose (F-18) (FDG PET/CT) is increasingly used in Kaposi sarcoma (KS), but its value has not been assessed. In this study, we aimed to evaluate the diagnostic accuracy of FDG PET/CT to define the extent of disease in KS. Consecutive patients with KS referred to our department for FDG PET/CT were included. The diagnostic accuracy of FDG PET/CT for cutaneous and extra-cutaneous KS staging was assessed on a per lesion basis compared to staging obtained from clinical examination, standard imaging, endoscopy, histological analyses, and follow-up. From 2007 to 2017, 75 patients with FDG PET/CT were analyzed. The sensitivity and specificity of FDG PET/CT for the overall detection of KS lesions were 71 and 98%, respectively. Sensitivity and specificity were 100 and 85% for lymph nodes, 87 and 98% for bone, 87 and 100% for lungs, and 100 and 100% for muscle involvement, whereas sensitivity was only 17% to detect KS digestive involvement. The sensitivity of the diagnostic for KS cutaneous involvement increased from 73 to 88% when using a whole-body examination. FDG PET/CT showed good sensitivity and specificity for KS staging (digestive involvement excepted) and could be used for staging patients with active KS.
Sections du résumé
BACKGROUND
BACKGROUND
Positron emission tomography/computed tomography with fluorodeoxyglucose (F-18) (FDG PET/CT) is increasingly used in Kaposi sarcoma (KS), but its value has not been assessed.
OBJECTIVES
OBJECTIVE
In this study, we aimed to evaluate the diagnostic accuracy of FDG PET/CT to define the extent of disease in KS.
METHODS
METHODS
Consecutive patients with KS referred to our department for FDG PET/CT were included. The diagnostic accuracy of FDG PET/CT for cutaneous and extra-cutaneous KS staging was assessed on a per lesion basis compared to staging obtained from clinical examination, standard imaging, endoscopy, histological analyses, and follow-up.
RESULTS
RESULTS
From 2007 to 2017, 75 patients with FDG PET/CT were analyzed. The sensitivity and specificity of FDG PET/CT for the overall detection of KS lesions were 71 and 98%, respectively. Sensitivity and specificity were 100 and 85% for lymph nodes, 87 and 98% for bone, 87 and 100% for lungs, and 100 and 100% for muscle involvement, whereas sensitivity was only 17% to detect KS digestive involvement. The sensitivity of the diagnostic for KS cutaneous involvement increased from 73 to 88% when using a whole-body examination.
CONCLUSION
CONCLUSIONS
FDG PET/CT showed good sensitivity and specificity for KS staging (digestive involvement excepted) and could be used for staging patients with active KS.
Identifiants
pubmed: 35565319
pii: cancers14092189
doi: 10.3390/cancers14092189
pmc: PMC9102885
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Am Acad Dermatol. 2019 Aug;81(2):448-455
pubmed: 30902727
Clin Nucl Med. 2011 Mar;36(3):231-4
pubmed: 21285687
PLoS One. 2012;7(11):e46967
pubmed: 23226197
Cancer. 2007 Mar 15;109(6):1040-52
pubmed: 17265518
Clin Nucl Med. 2012 Jul;37(7):692-3
pubmed: 22691516
Eur J Cancer. 2019 Jun;114:117-127
pubmed: 31096150
J Acquir Immune Defic Syndr. 2010 Aug;54(4):444-6
pubmed: 20611036
AJR Am J Roentgenol. 2011 Aug;197(2):284-94
pubmed: 21785073
AIDS Res Ther. 2011 Sep 28;8:34
pubmed: 21955517
J Gastrointestin Liver Dis. 2013 Dec;22(4):441-5
pubmed: 24369327
J Cancer Res Ther. 2012 Jan-Mar;8(1):112-3
pubmed: 22531526
Jpn J Radiol. 2010 Dec;28(10):759-62
pubmed: 21191742
Radiographics. 2006 Jul-Aug;26(4):1169-85
pubmed: 16844940
Mol Imaging Radionucl Ther. 2018 Feb 1;27(1):32-36
pubmed: 29393052
Transplant Rev (Orlando). 2008 Oct;22(4):252-61
pubmed: 18656341
J Clin Oncol. 2005 Apr 1;23(10):2433; author reply 2433-4
pubmed: 15800341
Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):555-556
pubmed: 27832310
Clin Oncol (R Coll Radiol). 2017 Oct;29(10):e165-e171
pubmed: 28610760
J Am Acad Dermatol. 2013 Feb;68(2):313-31
pubmed: 22695100
Ann Oncol. 2018 Apr 1;29(4):1067-1069
pubmed: 29324995
J Infect Dis. 2015 Oct 15;212(8):1250-60
pubmed: 25828248
Radiat Prot Dosimetry. 2016 Jun;169(1-4):365-70
pubmed: 26940437
J Am Acad Dermatol. 2008 Aug;59(2):179-206; quiz 207-8
pubmed: 18638627
Clin Oncol (R Coll Radiol). 2012 May;24(4):309-11
pubmed: 22449790
Medicine (Baltimore). 2014 Sep;93(11):e67
pubmed: 25192485
Crit Rev Oncol Hematol. 1996 Nov;24(3):153-63
pubmed: 8894401
Pan Afr Med J. 2016 Apr 15;23:196
pubmed: 27347285
Ir J Med Sci. 2013 Dec;182(4):745-6
pubmed: 23526254
J Nucl Med. 2016 Oct;57(10):1642-1649
pubmed: 27230933
J HIV Ther. 2008 Sep;13(3):65-71
pubmed: 19039297
World J Gastrointest Pharmacol Ther. 2015 Aug 6;6(3):89-95
pubmed: 26261737
Pol Arch Intern Med. 2021 Jan 29;131(1):78-80
pubmed: 33306291
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1279-1288
pubmed: 29616304
Int J STD AIDS. 1997 Nov;8(11):709-12
pubmed: 9363548
Mol Imaging Radionucl Ther. 2016 Oct 5;25(3):140-142
pubmed: 27751977
Laryngoscope. 2013 Feb;123(2):404-6
pubmed: 22778055
J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):150-7
pubmed: 22395672
HIV Med. 2013 Sep;14(8):455-62
pubmed: 23517190
An Bras Dermatol. 2017 Mar-Apr;92(2):172-176
pubmed: 28538874